New hope for young women with bone loss from missed periods
NCT ID NCT06533865
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding romosozumab to standard estrogen therapy improves bone density in girls and women aged 14-30 who have stopped menstruating due to intense exercise, stress, or an eating disorder. Participants receive either romosozumab or a placebo for 6 months, plus estrogen patches and progesterone pills, followed by one IV dose of zoledronate. The goal is to see if the combination leads to stronger bones compared to placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FHA (FUNCTIONAL HYPOTHALAMIC AMENORRHEA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
University of Virginia Medical Center
RECRUITINGCharlottesville, Virginia, 22903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lifting weights, not rest: new study tests exercise as treatment for lost periods
- New online program aims to help women with missed periods
- New study combines eastern and western medicine to restore periods in women
- Can a patch beat a pill? new study aims to strengthen bones in women with hormone imbalance
- Study reveals how cutting calories disrupts Women's periods
- Teen bone health under the microscope: new study looks at why some girls develop weak bones